Treating the Different Phenotypes of Behçet's Syndrome

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Behçet's syndrome (BS) is a multisystemic vasculitis with diverse clinical manifestations, making it challenging to treat as a single entity.
• Evidence suggests distinct BS phenotypes characterized by specific co-existing involvements, necessitating tailored treatment strategies.
• Current management guidelines focus on individual manifestations, potentially overlooking the benefits of phenotype-specific therapeutic approaches.

Purpose of the Study:

• To review and summarize current evidence on pharmacological treatments for major Behçet's syndrome phenotypes.
• To highlight the potential of phenotype-based treatment strategies for personalized medicine in BS.
• To provide a comprehensive overview of first-, second-, and third-line treatment options for distinct BS phenotypes.

Main Methods:

• Literature review of current evidence on pharmacological treatments for Behçet's syndrome.
• Categorization of treatments based on three major BS phenotypes: mucocutaneous/articular, extra-parenchymal neurological/peripheral vascular, and parenchymal neurological/ocular.
• Analysis of first-, second-, and third-line treatment options for each identified phenotype.

Main Results:

• Identification of specific pharmacological treatments for each of the three major BS phenotypes.
• Summary of evidence supporting the efficacy of various treatments within each phenotype category.
• Highlighting the heterogeneity in treatment responses across different BS phenotypes.

Conclusions:

• Tailoring pharmacological treatments to specific Behçet's syndrome phenotypes is a promising strategy for personalized medicine.
• Phenotype-specific treatment approaches may offer improved outcomes compared to managing individual disease manifestations.
• Further research is warranted to refine treatment guidelines based on distinct BS phenotypes.